Atalaya Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Atalaya Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-278,437	Closed	-$16.7K	–	302
2022 Q4	$16.7K	Hold	278,437	–	–	﹤0.01%	169
2022 Q3	$17K	Hold	278,437	–	–	﹤0.01%	252
2022 Q2	$11K	Hold	278,437	–	–	﹤0.01%	271
2022 Q1	$67K	Hold	278,437	–	–	0.01%	268
2021 Q4	$181K	Hold	278,437	–	–	0.02%	257
2021 Q3	$184K	Hold	278,437	–	–	0.03%	192
2021 Q2	$239K	Hold	278,437	–	–	0.06%	168
2021 Q1	$170K	Buy	+278,437	New	+$196K	0.04%	175

Atalaya Capital Management's BIOTW Position: Q1 2023 in Review

Atalaya Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 278,437 shares — an estimated $16.7K sold.

Atalaya Capital Management first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $239K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Atalaya Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Atalaya Capital Management sold 278,437 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $16.7K.
Atalaya Capital Management first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Atalaya Capital Management's Biotech Acquisition Company Warrant position peaked at $239K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Atalaya Capital Management's 13F filing for Q1 2023, filed 11 May 2023.